Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled multicenter study of Secukinumab (AIN457) to examine the clinical efficacy and the NSAID-sparing effect of Secukinumab over 16 weeks in patients with ankylosing spondylitis (ASTRUM)

Next Previous
Trial Profile

A randomized, double-blind, placebo-controlled multicenter study of Secukinumab (AIN457) to examine the clinical efficacy and the NSAID-sparing effect of Secukinumab over 16 weeks in patients with ankylosing spondylitis (ASTRUM)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Therapeutic Use
  • Acronyms ASTRUM
  • Sponsors Novartis; Novartis Pharmaceuticals

Most Recent Events

  • 09 Nov 2021 Results evaluating the short-term NSAID sparing effect of secukinumab in Ankylosing Spondylitis Patients with NSAID intake, presented at the ACR Convergence 2021
  • 05 Jun 2021 Primary endpoint (Proportion of Patients Who Achieved ASAS20 Response in the Pooled Secukinumab Group Compared With the Placebo Group at Week 12) has not been met as per results presented at the 22nd Annual Congress of the European League Against Rheumatism
  • 05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top